Company Overview
Company Type: Private Company
Website: replicor.com
Number of Employees: -
Year Founded: 1998
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Replicor Inc., a biopharmaceutical company, develops and commercializes novel nucleic acid-based polymers (NAPs) for the treatment of patients with Hepatitis B (HBV) and Hepatitis D. Its NAPs therapy can be engineered with sequences, which retain antiviral activity that do not have pro-inflammatory activity or off target effects common with other oligonucleotide-based drugs. The company offers therapeutic agents to eliminate HBV virus (HBsAg) in the blood seroconversion for HBsAg and HBeAg, and serum HBV DNA; and reduce cccDNA levels in the liver. Replicor Inc. was founded in 1998 and is based in Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Bazinet, Michel 
Chief Executive Officer and Chief Medical Officer
Vaillant, Andrew 
Chief Scientific Officer
Bazinet, Léo 
Vice President of Administration

Key Board Members
Name
Title
Kornbrust, Douglas J.
Member of Scientific Advisory Board
Lockridge, Jennifer 
Member of Scientific Advisory Board
Roggendorf, Michael 
Member of Scientific Advisory Board
Trepo, Christian 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
6100, Royalmount Avenue | Montreal, QC | H4P 2R2 | Canada
Fax: 514-496-9021

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
VR Adviser, LLC
Jul-02-2015
Minority
-
Growth
Bong Koh
Silver Rock Group
-
Unknown
-
-
-

Prior Investors
Silver Rock Capital, T2C2 Capital, T2C2/Bio 2000, L.P., T2C2/Bio, L.P.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-2-2015
Jul-2-2015
Private Placement
Target
Replicor Inc.
VR Adviser, LLC

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-14-2022
Company Conference Presentations
Replicor Inc. Presents at World Vaccine Congress Europe 2022, Oct-14-2022 12:30 PM
Dec-02-2021
Company Conference Presentations
Replicor Inc. Presents at World Antiviral Congress 2021, Nov-30-2021 through Dec-02-2021
Dec-01-2021
Company Conference Presentations
Replicor Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 through Dec-02-2021
Sep-28-2017
Product-Related Announcements
Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in the Lancet Gastroenterology & Hepatology
Sep-25-2017
Company Conference Presentations
Replicor Inc. Presents at Cambridge Healthtech Institute's 15th Annual Discovery on Target, Sep-25-2017 08:10 AM


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 04:04 AM
Replicor Inc.
Replicor Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
58
GlobalData

Sep 14, 2023 07:13 PM
Replicor Inc.
Replicor Inc
Reports
75
GlobalData

Dec 14, 2022 01:25 AM
Replicor Inc.
Replicor Inc
Reports
73
GlobalData

Dec 10, 2022 12:38 AM
Replicor Inc.
Replicor Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
56
GlobalData

Sep 22, 2022 04:41 AM
Replicor Inc.
Replicor Inc
Reports
73
GlobalData

Sep 15, 2022 05:05 AM
Replicor Inc.
Replicor Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
56
GlobalData

Jun 18, 2022 02:45 AM
Replicor Inc.
Replicor Inc
Reports
73
GlobalData

Jun 10, 2022 10:52 AM
Replicor Inc.
Replicor Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
56
GlobalData

Mar 15, 2022 04:05 AM
Replicor Inc.
Replicor Inc
Reports
73
GlobalData

Mar 11, 2022 05:32 AM
Replicor Inc.
Replicor Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
56


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Kornbrust, Douglas J.
Member of Scientific Advisory Board
-
514-496-9021

Lockridge, Jennifer 
Member of Scientific Advisory Board
-
514-496-9021
-
Roggendorf, Michael 
Member of Scientific Advisory Board
-
514-496-9021

Trepo, Christian 
Member of Scientific Advisory Board
-
514-496-9021

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bazinet, Michel 
Chief Executive Officer and Chief Medical Officer
-
514-496-9021
-
Vaillant, Andrew 
Chief Scientific Officer
-
514-496-9021

Bazinet, Léo 
Vice President of Administration
-
514-496-9021

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
